PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
PHI secures a loan facility of in total SEK 7 million
PHI announces that the Company has secured a loan facility of in total SEK 7 million from Bizcap AB, and from that loan facility decided to draw a tranche of SEK 4.5 million.
PostNews: Press Release
PHI announces conference schedule for spring 2024
PHI is pleased to announce a strategic activity schedule for spring 2024, during which PHI will participate in select industry webinars and events.
PostNews: Interim Report
Interim Report 3 2023/24
This quarter set new records for PHI, achieving our highest-ever sales and advancing our strategic initiatives significantly. The strengthening of our partnership with Altium and the expanding reach of QPI technology highlights our leading position in the field. This quarter truly shows our continuous progress toward our core mission: making cell-based therapies accessible, affordable, and safe for all.
PostNews
BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
PostNews: Press Release
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024
On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
PostNews: Press Release
Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing
PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
No Blood, No Tumor
Scientists at Boston Children’s Hospital have used HoloMonitor to study living bone cancer cells. By studying their dynamics, they have successfully for the first time distinguished aggressive bone cancer cells that promote blood vessel formation from the harmless counterparts that do not promote blood vessel formation.
Big Data, Fewer Cells
Scientists at Holographic Imaging Cytometry Program of Excellence at Northeastern University have developed a method to compare time series data of drug treated cells with untreated cells.
3D Culture
Using HoloMonitor and a public domain image processing software called Image J, the researchers from Northeastern University have developed a method for cell experiments based on cells cultured in a 3-dimensional collagen gel. They show that this new method is clearly superior to conventional methods, based on cells cultured on a 2-dimensional.
Big Pharma, Big Data
Imaged-based time-lapse cytometers, as our HoloMonitor, creates huge amounts of information on how cells interact and multiply over long time periods. Combined with Big Data technology, such novel instrumentation will provide cell biologists and the pharmaceutical industry with a game changing new tool to better understand complex cellular interactions and through this hopefully cure cancer.
